What is Pulmatrix?
Pulmatrix is at the forefront of developing novel inhaled therapies designed to combat severe lung conditions such as allergic bronchopulmonary aspergillosis (ABPA) and Chronic Obstructive Pulmonary Disease (COPD), as well as neurological disorders like acute migraine. The company's core innovation lies in its patented iSPERSE technology, an engineered dry powder delivery platform. This platform aims to optimize therapeutic delivery directly to the lungs, enhancing local drug concentrations while minimizing systemic side effects, thereby improving patient outcomes. The company's strategic capital infusions underscore its commitment to advancing its product pipeline through rigorous clinical development.
How much funding has Pulmatrix raised?
Pulmatrix has raised a total of $157.3M across 15 funding rounds:
Debt
$20.5M
Share Placement
$10M
Stock Offering
$9.7M
Stock Offering
$15.9M
Stock Offering
$3M
Multiple Rounds
$20.3M
Stock Offering
$8M
Private Equity
$1M
Debt (2013): $20.5M with participation from Undisclosed
Share Placement (2015): $10M led by 5AM Ventures, ARCH Ventures, Altitude Life Science Ventures, and Polaris Partners
Stock Issuance/Offering (2017): $9.7M supported by Undisclosed
Stock Issuance/Offering (2018): $15.9M featuring Undisclosed
Stock Issuance/Offering (2018): $3M backed by Undisclosed
Stock Issuance/Offering (2019): $1.2M with participation from Undisclosed
Stock Issuance/Offering (2019): $2.5M led by Undisclosed
Stock Issuance/Offering (2019): $16.6M supported by Undisclosed
Stock Issuance/Offering (2020): $8M featuring Undisclosed
Private Equity (2026): $1M, investors not publicly disclosed
Key Investors in Pulmatrix
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth. Their team consists of board members, entrepreneurs, scientists, and operators who engage deeply to foster innovation and collaboration. Polaris aims to support the development of modern solutions in various industries, exemplifying a commitment to nurturing relationships and enhancing the entrepreneurial journey.
ARCH Ventures
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Pulmatrix?
The substantial enterprise-level funding and recent strategic investment position Pulmatrix for accelerated development and potential commercialization of its innovative inhaled therapies. This capital infusion is expected to fuel further research and development efforts, expand clinical trial activities, and potentially scale manufacturing capabilities. The company's focus on addressing significant unmet medical needs in respiratory and neurological diseases, coupled with its advanced iSPERSE delivery technology, suggests a strong potential for future growth and market penetration. Pulmatrix's strategic financing rounds indicate a clear path toward advancing its pipeline and achieving key developmental milestones.
See full Pulmatrix company page
